- Aldeyra Therapeutics Inc ADX-629 Results Call TranscriptDec 19, 2023
- Aldeyra Therapeutics Inc Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 Call TranscriptJun 29, 2023
- Aldeyra Therapeutics Inc Top-Line Results from the Phase 2 Clinical Trial of ADX-629 in Patients with Chronic Cough Call TranscriptJun 27, 2023
- Aldeyra Therapeutics Inc Top-Line Results from the Phase 3 INVIGORATE-2 Trial in Allergic Conjunctivitis Call TranscriptJun 15, 2023
- Aldeyra Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q4 2022 Aldeyra Therapeutics Inc Earnings Call TranscriptMar 09, 2023$7.9 (+7.19%)Earnings
- Q3 2022 Aldeyra Therapeutics Inc Earnings Call TranscriptNov 10, 2022$5.5 (+6.18%)Earnings
- Aldeyra Therapeutics Inc to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Call TranscriptOct 06, 2022
- Q2 2022 Aldeyra Therapeutics Inc Earnings Call TranscriptAug 05, 2022$6.92 (+10.90%)Earnings
- Aldeyra Therapeutics Inc Call to Report Top-Line Results from the Crossover Clinical Trial of Reproxalap TranscriptJul 12, 2022
- Aldeyra Therapeutics Inc TRANQUILITY-2 Top-Line Data Results Call TranscriptJun 08, 2022
- Q1 2022 Aldeyra Therapeutics Inc Earnings Call TranscriptMay 05, 2022$2.78 (-5.12%)Earnings
- Aldeyra Therapeutics Inc Research & Development Day TranscriptMar 29, 2022
- Q4 2021 Aldeyra Therapeutics Inc Earnings Call TranscriptMar 17, 2022$4.86 (+16.27%)Earnings
- Aldeyra Therapeutics Inc Conference Call and Webcast TranscriptDec 20, 2021
- Q3 2021 Aldeyra Therapeutics Inc Earnings Call TranscriptOct 28, 2021$9 (+9.22%)Earnings
- Aldeyra Therapeutics Inc at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Aldeyra Therapeutics Inc Earnings Call TranscriptAug 05, 2021$9.57 (+8.26%)Earnings
- Q1 2021 Aldeyra Therapeutics Inc Earnings Call TranscriptMay 06, 2021$12.05 (+0.67%)Earnings
- Aldeyra Therapeutics Inc Provide Results from the Phase 3 Invigorate Clinical Trial Corporate Call TranscriptApr 27, 2021
- Q4 2020 Aldeyra Therapeutics Inc Earnings Call TranscriptMar 11, 2021$12.07 (-0.08%)Earnings
- Aldeyra Therapeutics, Inc. - Special Call TranscriptJan 07, 2021
- Q3 2020 Aldeyra Therapeutics Inc Earnings Call TranscriptNov 05, 2020$6.95 (+2.36%)Earnings
- Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel TranscriptSep 10, 2020
- Q2 2020 Aldeyra Therapeutics Inc Earnings Call TranscriptAug 06, 2020$6.76 (-9.38%)Earnings
- Aldeyra Therapeutics, Inc. - Special Call TranscriptMay 20, 2020
- Q1 2020 Aldeyra Therapeutics Inc Earnings Call TranscriptMay 07, 2020$2.83 (-3.41%)Earnings
- Q4 2019 Aldeyra Therapeutics Inc Earnings Call TranscriptMar 12, 2020$2.42 (-13.26%)Earnings
- Aldeyra Therapeutics Inc Corporate Analyst Meeting TranscriptFeb 24, 2020
- Aldeyra Therapeutics, Inc. - Special Call TranscriptDec 03, 2019
- Q3 2019 Aldeyra Therapeutics Inc Earnings Call TranscriptNov 07, 2019$5.76 (-4.48%)Earnings
- Aldeyra Therapeutics, Inc. - Special Call TranscriptOct 31, 2019
- Q2 2019 Aldeyra Therapeutics Inc Earnings Call TranscriptAug 08, 2019$5.4 (-0.74%)Earnings
- Aldeyra Therapeutics, Inc. - Special Call TranscriptJun 25, 2019
- Q1 2019 Aldeyra Therapeutics Inc Earnings Call TranscriptMay 09, 2019$8.03 (+0.63%)Earnings
- Aldeyra Therapeutics, Inc. - Special Call TranscriptMar 26, 2019
- Q4 2018 Aldeyra Therapeutics Inc Earnings Call TranscriptMar 08, 2019$7.53 (-3.71%)Earnings
- Aldeyra Therapeutics, Inc. - Special Call TranscriptFeb 28, 2019
Q3 2019 Aldeyra Therapeutics Inc Earnings Call Transcript
Good morning, and welcome to the Aldeyra Therapeutics Third Quarter 2019 Financial Results Conference Call. My name is Andrea, and I will be your operator today. (Operator Instructions) At this time, I would like to turn the call over to Mr. Joshua Reed, the company's Chief Financial Officer. Please go ahead, sir.
Good morning, everyone. With me today is Dr. Todd Brady, Chief Executive Officer. Todd will begin today's call with an overview of our strategy and recent highlights. I will discuss our Q3 results. Todd will make some concluding comments, and then we will be happy to take your questions.
Please note that this morning's conference call contains forward-looking statements regarding future events and the future performance of Aldeyra. Forward-looking statements include statements regarding Aldeyra's possible or assumed future results of operations, expenses and financial position, business strategies and plans, research, development and commercial plans or expectations, trends, market sizing,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)